vs
Side-by-side financial comparison of CB Financial Services, Inc. (CBFV) and STRATA Skin Sciences, Inc. (SSKN). Click either name above to swap in a different company.
CB Financial Services, Inc. is the larger business by last-quarter revenue ($13.8M vs $9.3M, roughly 1.5× STRATA Skin Sciences, Inc.). On growth, CB Financial Services, Inc. posted the faster year-over-year revenue change (19.9% vs -3.0%). CB Financial Services, Inc. produced more free cash flow last quarter ($17.2M vs $-551.0K). Over the past eight quarters, STRATA Skin Sciences, Inc.'s revenue compounded faster (17.3% CAGR vs 1.2%).
CB Bank is one of Myanmar's largest commercial banks. It became the first bank in Myanmar to issue ATM cards and credit cards. The bank, led by U Khin Maung Aye (Chairman) and U Kyaw Thu Ko (CEO) has over 245 branches across the country.
Strata Skin Sciences is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.
CBFV vs SSKN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.8M | $9.3M |
| Net Profit | — | $58.0K |
| Gross Margin | — | 61.8% |
| Operating Margin | 38.1% | 5.3% |
| Net Margin | — | 0.6% |
| Revenue YoY | 19.9% | -3.0% |
| Net Profit YoY | — | 101.3% |
| EPS (diluted) | $0.90 | $0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.8M | $9.3M | ||
| Q3 25 | $2.4M | $6.9M | ||
| Q2 25 | $13.5M | $7.7M | ||
| Q1 25 | $12.1M | $6.8M | ||
| Q4 24 | $13.2M | $9.6M | ||
| Q3 24 | $12.7M | $8.8M | ||
| Q2 24 | $12.2M | $8.4M | ||
| Q1 24 | $13.5M | $6.8M |
| Q4 25 | — | $58.0K | ||
| Q3 25 | $-5.7M | $-1.6M | ||
| Q2 25 | $3.9M | $-2.6M | ||
| Q1 25 | $1.9M | $-2.1M | ||
| Q4 24 | — | $-4.6M | ||
| Q3 24 | $3.2M | $-2.1M | ||
| Q2 24 | $2.6M | $-91.0K | ||
| Q1 24 | $4.2M | $-3.4M |
| Q4 25 | — | 61.8% | ||
| Q3 25 | — | 60.4% | ||
| Q2 25 | — | 56.2% | ||
| Q1 25 | — | 53.5% | ||
| Q4 24 | — | 61.4% | ||
| Q3 24 | — | 60.1% | ||
| Q2 24 | — | 59.0% | ||
| Q1 24 | — | 45.6% |
| Q4 25 | 38.1% | 5.3% | ||
| Q3 25 | -289.8% | -16.9% | ||
| Q2 25 | 35.0% | -30.1% | ||
| Q1 25 | 19.3% | -25.0% | ||
| Q4 24 | 23.1% | -44.7% | ||
| Q3 24 | 31.2% | -18.2% | ||
| Q2 24 | 26.4% | -5.7% | ||
| Q1 24 | 37.9% | -42.7% |
| Q4 25 | — | 0.6% | ||
| Q3 25 | -235.2% | -23.4% | ||
| Q2 25 | 29.3% | -33.6% | ||
| Q1 25 | 15.8% | -31.2% | ||
| Q4 24 | — | -47.6% | ||
| Q3 24 | 25.3% | -23.6% | ||
| Q2 24 | 21.8% | -1.1% | ||
| Q1 24 | 31.1% | -49.8% |
| Q4 25 | $0.90 | $0.14 | ||
| Q3 25 | $-1.07 | $-0.36 | ||
| Q2 25 | $0.74 | $-0.62 | ||
| Q1 25 | $0.35 | $-0.51 | ||
| Q4 24 | $0.45 | $-2.01 | ||
| Q3 24 | $0.60 | $-0.51 | ||
| Q2 24 | $0.51 | $-0.03 | ||
| Q1 24 | $0.82 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $31.7M | $7.9M |
| Total DebtLower is stronger | — | $15.3M |
| Stockholders' EquityBook value | $157.5M | $2.9M |
| Total Assets | $1.5B | $30.5M |
| Debt / EquityLower = less leverage | — | 5.28× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.7M | $7.9M | ||
| Q3 25 | $55.9M | $7.1M | ||
| Q2 25 | $64.5M | $6.0M | ||
| Q1 25 | $61.3M | $6.5M | ||
| Q4 24 | $49.6M | $7.3M | ||
| Q3 24 | $147.3M | $7.1M | ||
| Q2 24 | $142.6M | $5.5M | ||
| Q1 24 | $73.7M | $5.2M |
| Q4 25 | — | $15.3M | ||
| Q3 25 | — | $15.3M | ||
| Q2 25 | — | $15.0M | ||
| Q1 25 | — | $15.0M | ||
| Q4 24 | — | $15.0M | ||
| Q3 24 | — | $15.0M | ||
| Q2 24 | — | $15.0M | ||
| Q1 24 | — | $15.0M |
| Q4 25 | $157.5M | $2.9M | ||
| Q3 25 | $152.5M | $1.3M | ||
| Q2 25 | $148.4M | $532.0K | ||
| Q1 25 | $148.3M | $3.0M | ||
| Q4 24 | $147.4M | $5.0M | ||
| Q3 24 | $149.1M | $9.4M | ||
| Q2 24 | $142.9M | $9.5M | ||
| Q1 24 | $141.6M | $9.4M |
| Q4 25 | $1.5B | $30.5M | ||
| Q3 25 | $1.5B | $30.7M | ||
| Q2 25 | $1.5B | $29.5M | ||
| Q1 25 | $1.5B | $33.0M | ||
| Q4 24 | $1.5B | $34.9M | ||
| Q3 24 | $1.6B | $39.4M | ||
| Q2 24 | $1.6B | $38.8M | ||
| Q1 24 | $1.5B | $39.2M |
| Q4 25 | — | 5.28× | ||
| Q3 25 | — | 11.65× | ||
| Q2 25 | — | 28.20× | ||
| Q1 25 | — | 5.04× | ||
| Q4 24 | — | 3.02× | ||
| Q3 24 | — | 1.60× | ||
| Q2 24 | — | 1.58× | ||
| Q1 24 | — | 1.59× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $17.8M | $-239.0K |
| Free Cash FlowOCF − Capex | $17.2M | $-551.0K |
| FCF MarginFCF / Revenue | 124.1% | -5.9% |
| Capex IntensityCapex / Revenue | 4.7% | 3.4% |
| Cash ConversionOCF / Net Profit | — | -4.12× |
| TTM Free Cash FlowTrailing 4 quarters | $29.5M | $-4.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $17.8M | $-239.0K | ||
| Q3 25 | $4.6M | $-64.0K | ||
| Q2 25 | $4.1M | $-1.9M | ||
| Q1 25 | $4.0M | $-550.0K | ||
| Q4 24 | $6.8M | $703.0K | ||
| Q3 24 | $3.1M | $-302.0K | ||
| Q2 24 | $-1.2M | $591.0K | ||
| Q1 24 | $3.3M | $-804.0K |
| Q4 25 | $17.2M | $-551.0K | ||
| Q3 25 | $4.5M | $-1.1M | ||
| Q2 25 | $3.9M | $-2.0M | ||
| Q1 25 | $3.9M | $-749.0K | ||
| Q4 24 | $3.4M | $199.0K | ||
| Q3 24 | $2.2M | $-364.0K | ||
| Q2 24 | $-2.4M | $246.0K | ||
| Q1 24 | $2.3M | $-1.5M |
| Q4 25 | 124.1% | -5.9% | ||
| Q3 25 | 186.5% | -15.6% | ||
| Q2 25 | 28.8% | -26.1% | ||
| Q1 25 | 32.5% | -11.0% | ||
| Q4 24 | 26.0% | 2.1% | ||
| Q3 24 | 17.4% | -4.1% | ||
| Q2 24 | -19.6% | 2.9% | ||
| Q1 24 | 17.0% | -22.6% |
| Q4 25 | 4.7% | 3.4% | ||
| Q3 25 | 4.3% | 14.7% | ||
| Q2 25 | 1.9% | 0.8% | ||
| Q1 25 | 0.8% | 2.9% | ||
| Q4 24 | 25.1% | 5.3% | ||
| Q3 24 | 6.7% | 0.7% | ||
| Q2 24 | 10.0% | 4.1% | ||
| Q1 24 | 7.2% | 10.7% |
| Q4 25 | — | -4.12× | ||
| Q3 25 | — | — | ||
| Q2 25 | 1.05× | — | ||
| Q1 25 | 2.11× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.95× | — | ||
| Q2 24 | -0.44× | — | ||
| Q1 24 | 0.78× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CBFV
Segment breakdown not available.
SSKN
| Dermatology Recurring Procedures | $6.1M | 65% |
| Dermatology Procedures Equipment | $3.2M | 35% |
